This site is intended for healthcare professionals

CPD
CPD
Pro
Pro
account_circleSign in
Go to /sign-in page

You can view 5 more pages before signing in

Go to /pro/cpd-dashboard page

This page is worth 0.05 CPD credits. CPD dashboard

Go to /account/subscription-details page

This page is worth 0.05 CPD credits. Upgrade to Pro

UKPDS 39 trial

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

The UKPDS 39 trial aimed to determine whether a beta-blocker or an angiotensin converting enzyme inhibitor had a specific advantage or disadvantage in the prevention of macrovascular and microvascular complications of type 2 diabetes.

The trial randomly assigned patients to tight control of blood pressure (aim <150/85 mmHg) with captopril or atenolol.

Reference:

  • 1) UK Prospective Diabetes Study Group (1998). Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complication in type 2 diabetes: UKPDS 39. BMJ, 317, 713-720.

Related pages

Create an account to add page annotations

Create a free account

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.